ES2222615T3 - Uso de derivados de vitamina d para potenciar la eficacia de agentes citotoxicos. - Google Patents

Uso de derivados de vitamina d para potenciar la eficacia de agentes citotoxicos.

Info

Publication number
ES2222615T3
ES2222615T3 ES98957308T ES98957308T ES2222615T3 ES 2222615 T3 ES2222615 T3 ES 2222615T3 ES 98957308 T ES98957308 T ES 98957308T ES 98957308 T ES98957308 T ES 98957308T ES 2222615 T3 ES2222615 T3 ES 2222615T3
Authority
ES
Spain
Prior art keywords
vitamin
tumor
derivative
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957308T
Other languages
English (en)
Spanish (es)
Inventor
Candace Johnson
Donald Trump
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Application granted granted Critical
Publication of ES2222615T3 publication Critical patent/ES2222615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES98957308T 1997-08-29 1998-08-27 Uso de derivados de vitamina d para potenciar la eficacia de agentes citotoxicos. Expired - Lifetime ES2222615T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US921170 1997-08-29
US08/921,170 US6087350A (en) 1997-08-29 1997-08-29 Use of pretreatment chemicals to enhance efficacy of cytotoxic agents

Publications (1)

Publication Number Publication Date
ES2222615T3 true ES2222615T3 (es) 2005-02-01

Family

ID=25445023

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957308T Expired - Lifetime ES2222615T3 (es) 1997-08-29 1998-08-27 Uso de derivados de vitamina d para potenciar la eficacia de agentes citotoxicos.

Country Status (10)

Country Link
US (5) US6087350A (enExample)
EP (2) EP1030670B1 (enExample)
JP (1) JP2001517705A (enExample)
AT (1) ATE269089T1 (enExample)
AU (1) AU1359499A (enExample)
DE (1) DE69824622T2 (enExample)
DK (1) DK1030670T3 (enExample)
ES (1) ES2222615T3 (enExample)
PT (1) PT1030670E (enExample)
WO (1) WO1999016451A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
CA2401304A1 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
AU2001293473A1 (en) * 2000-09-18 2002-03-26 Mayne Pharma International Pty Ltd Diphosphonate solutions
AU2001291239A1 (en) * 2000-10-06 2002-04-22 Abbott Laboratories Use of vitamin d2 compounds for alopecia
US7091241B2 (en) * 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US20070043110A1 (en) * 2001-06-01 2007-02-22 Summa Health System Nontoxic potentiation sensitization of ovarian cancer therapy by supplementary treatment with vitamins
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
WO2004000237A2 (en) * 2002-06-24 2003-12-31 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of mdr cancer with adenosine a3 antagonists
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
WO2005094358A2 (en) * 2004-03-29 2005-10-13 Roswell Park Cancer Institute Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs
US20050222190A1 (en) * 2004-03-30 2005-10-06 Curd John G 1,4-bis-N-oxide azaanthracenediones and the use thereof
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
SG173119A1 (en) * 2009-01-27 2011-08-29 Berg Biosystems Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
US9061040B2 (en) 2011-08-15 2015-06-23 Mihai Ciustea Combination therapy for breast cancer
US20190038641A1 (en) * 2016-02-04 2019-02-07 The Board Of Regents Of The University Of Texas System Combination therapy for castration-resistant prostrate cancer
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2021091449A1 (en) 2019-11-08 2021-05-14 Telefonaktiebolaget Lm Ericsson (Publ) Determining phase tracking reference signals in multiple transmission points

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3741996A (en) * 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US4670190A (en) * 1973-01-10 1987-06-02 Hesse Robert H 1-α-hydroxy vitamin D compounds and process for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4160803A (en) * 1978-03-23 1979-07-10 Corning Glass Works Self packaged test kit
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4508651A (en) * 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5321016A (en) * 1986-10-30 1994-06-14 Sandoz Pharmaceuticals Corp. Use of certain substituted α-amino acids in treating stress-related psychiatric disorders
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
EP0296800B1 (en) * 1987-06-23 1991-10-16 Yamanouchi Pharmaceutical Co. Ltd. Vitamin d3 derivatives
US4902481A (en) * 1987-12-11 1990-02-20 Millipore Corporation Multi-well filtration test apparatus
US4804502A (en) 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US5087619A (en) * 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5321018A (en) * 1989-03-09 1994-06-14 Wisconsin Alumni Research Foundation Use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
US5219528A (en) * 1989-07-28 1993-06-15 Pierce Chemical Company Apparatus for rapid immunoassays
DE4011682A1 (de) * 1990-04-06 1991-10-10 Schering Ag 24-oxa-derivate in der vitamin d-reihe
US5194248A (en) * 1990-06-21 1993-03-16 Trustees Of Boston University Compositions comprising vitamin D analog precursors and the use thereof
US6025346A (en) * 1990-09-21 2000-02-15 Bone Care International, Inc. 1α-hydroxy vitamin D4 and novel intermediates and analogues
PL170447B1 (en) * 1990-09-21 1996-12-31 Lunar Corp Method of obtaining novel 1 alpha-hydroxyvitamin d4 and novel transition and analog compounds
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
DE69233074T2 (de) * 1991-01-08 2004-03-18 Bone Care International Inc., Madison Verfahren zur Herstellung von 1-alpha-24-dihydroxy-Vitamin D2
US5789397A (en) * 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
DE4101953A1 (de) * 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
US5417923A (en) * 1991-04-24 1995-05-23 Pfizer Inc. Assay tray assembly
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
AU667675B2 (en) * 1991-06-28 1996-04-04 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
DE69213844T2 (de) * 1991-07-05 1997-04-10 Duphar Int Res Vitamin-D Derivat, Verfahren zu dessen Herstellung sowie Zwischenprodukte dafür
US5205989A (en) * 1991-09-18 1993-04-27 Minnesota Mining And Manufacturing Company Multi-well filtration apparatus
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DK0600079T3 (da) * 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
SK279913B6 (sk) * 1993-09-01 1999-05-07 Teijin Limited Farmaceutický prostriedok vo forme krému
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6040300A (en) * 1995-04-07 2000-03-21 Arch Development Corporation Method of preventing colon cancer with vitamin D3 analogues
US5616571A (en) 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
DE69606680T2 (de) * 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
DE19644049A1 (de) * 1995-11-11 1997-05-28 Basf Magnetics Gmbh Verfahren und Vorrichtung zum Demontieren von Bandkassetten
DE69626539T2 (de) 1995-11-20 2004-04-08 Kita, Kiyoshi, Shibuyaku topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
US6869940B2 (en) * 1995-12-28 2005-03-22 Chugai Seiyaku Kabushiki Kaisha Malignant tumor metastasis inhibitors
ATE290869T1 (de) * 1995-12-28 2005-04-15 Chugai Pharmaceutical Co Ltd Verwendung von vitamin d derivaten zur herstellung eines medikaments zur behandlung von bösartigen tumormetastase
AU710931B2 (en) * 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
DE19619036A1 (de) * 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5939456A (en) 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US5902906A (en) * 1997-05-01 1999-05-11 Albemarle Corporation Alkanethiolation process
US6187764B1 (en) * 1997-05-05 2001-02-13 Angelina Pinal Buttz A and D vitamins and their metabolites: A new treatment for seasonal allergic rhinitis and atopy
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
EP0998290B1 (en) 1997-06-06 2004-09-15 Wisconsin Alumni Research Foundation Use of vitamin d compounds to prevent transplant rejection
AUPO727097A0 (en) 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
US6359152B2 (en) * 1997-07-21 2002-03-19 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
AUPP332898A0 (en) 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
EP1123921A4 (en) * 1998-10-23 2003-08-20 Teijin Ltd VITAMIN D 3 DERIVATIVES? AND MEDICINES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THEM
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6524594B1 (en) * 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
ATE277889T1 (de) * 1999-07-16 2004-10-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
FR2798855B1 (fr) * 1999-09-28 2003-04-25 Oreal Utilisation de complexes inorganiques-organiques dans une composition a usage topique
US6703380B2 (en) * 1999-09-29 2004-03-09 Colotech A/S Prevention of cancer
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
KR20020071876A (ko) * 1999-12-06 2002-09-13 레오 파마 에이/에스 ＩＬ-1β 및 ＴＮＦ-α의 억제제로서의 아미노벤조페논
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
WO2001066531A1 (de) * 2000-03-07 2001-09-13 Aventis Pharma Deutschland Gmbh Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
CN100469764C (zh) * 2000-06-15 2009-03-18 中外制药株式会社 维生素d衍生物
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
DK1436257T3 (da) * 2001-10-12 2007-06-25 Univ Johns Hopkins Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning

Also Published As

Publication number Publication date
DE69824622D1 (de) 2004-07-22
PT1030670E (pt) 2004-09-30
AU1359499A (en) 1999-04-23
US20030216359A1 (en) 2003-11-20
EP1030670B1 (en) 2004-06-16
US20030176403A1 (en) 2003-09-18
ATE269089T1 (de) 2004-07-15
US6559139B1 (en) 2003-05-06
DK1030670T3 (da) 2004-10-04
EP1030670A1 (en) 2000-08-30
DE69824622T2 (de) 2009-09-24
WO1999016451A1 (en) 1999-04-08
EP1491198A1 (en) 2004-12-29
JP2001517705A (ja) 2001-10-09
US20080003304A1 (en) 2008-01-03
US6087350A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
EP1030670B1 (en) Use of vitamin d derivatives to enhance efficacy of cytotoxic agents
AU2007200423B2 (en) Combination chemotherapy
ES2414708T3 (es) Tratamiento anticanceroso que comprende un bloqueante de H2, al menos un agente antiinflamatorio y un agente citotóxico
EP3034076B1 (en) Combined application of isothiocyanate compound and anti-cancer medicine
TWI222863B (en) Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents
TWI574692B (zh) 偏亞砷酸鈉於治療白血病及淋巴瘤之用途
US5756537A (en) Regime for paclitaxel in Kaposi's sarcoma patients
AU2001242581B2 (en) Combination therapies with vascular damaging activity
JP2015505313A (ja) 癌を治療するための併用療法
JP2022081527A (ja) 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
ES2268764T3 (es) Combinacion antitumoral de 1,4-dioxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platino.
AU2001242581A1 (en) Combination therapies with vascular damaging activity
AU2001243385A1 (en) Combination chemotherapy
ES2952205T3 (es) Uso de iones de cobre para potenciar los efectos terapéuticos del arsénico
KR20100120674A (ko) 콜레스타놀 유도체의 병용 용도
CN104117064B (zh) 异硫氰酸酯类化合物与激素类药物的联合应用
AU2007200452B2 (en) Combination chemotherapy
HK1072563A (en) Use of vitamin d derivatives to enhance efficacy of cytotoxic agents
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
EP3052091B1 (en) Sustained release formulations containing methylglyoxal and their therapeutic applications
UA79926C2 (en) Use of ecteinascidin in combination therapy for sarcoma treatment
ZA200207114B (en) Combination therapies with vascular damaging activity.